Cisplatin and Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer

Marcu, Loredana G.; Doorn, T van; Olver, Ian

doi:10.1080/02841860310004364

Cited by 65 publications

(41 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In particular, cisplatin in combination with etoposide and bleomycin is considered a curative treatment for testicular cancer and is beneficial in combination regimens for ovarian cancer and cancers of the bladder, head and neck, endometrium, esophagus, and lung (12)(13)(14)(15). Our data provide the first step in identifying heritable genes that put patients at Fig.…”

Section: Discussionmentioning

confidence: 99%

Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity

et al. 2004

View full text Add to dashboard Cite

Little is known about the genetic determinants explaining variation in sensitivity to chemotherapeutic cytotoxicity. We characterized the degree of cisplatin sensitivity, using lymphoblastoid cell lines derived from 10 Centre d'Etude du Polymorphisme Humain pedigrees. We estimated the heritability for susceptibility to cisplatin-induced cytotoxicity to be ϳ0.47; therefore, sensitivity to the cytotoxic effects of cisplatin is under appreciable genetic influence. Linkage analysis was performed, and the strongest signal (lod score, 2.16; empirical P ‫؍‬ 0.0005) was found on chromosome 1 at 44 cM. Susceptibility to cisplatin-induced cytotoxicity is likely due to multiple loci, with low locus-specific heritability contributing to the trait. These data show the power of using large pedigrees that have been extensively genotyped for evaluating the genetic contribution to sensitivity to cell growth inhibition by anticancer agents.

show abstract

Section: Discussionmentioning

confidence: 99%

Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity

et al. 2004

View full text Add to dashboard Cite

show abstract

“…While in the 80 s and early 90 s most of the schedules used high-dose weekly cisplatin administration, in the mid to late 90 s daily low-dose infusions were introduced and outcomes have continuously improved (Marcu et al 2003). The graph in Fig.…”

Section: Cisplatin and Radiotherapy In The Latest Clinical Trialsmentioning

confidence: 98%

A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment

Marcu

Yeoh

2009

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Head and neck cancer is the fifth most common cancer worldwide but the most common malignant disease site in central Asia. The treatment of head and neck cancer is one of the most challenging in clinical oncology because of the high content of hypoxic cells of the cancer which increases resistance to therapy and also because of the high capacity of the cancer to regrow during treatment. For unresectable tumours, radiotherapy and chemotherapy alone or more often in combination is the treatment of choice. The aim of this paper is to review current understanding of carcinogenesis of head and neck cancer in relation to predisposing risk factors in general and for specific sub-sites and how these risk factors interact with the main reported genetic alterations in the progression of the cancer. The implications of these changes in determining choice of therapy are also discussed from a brief historical perspective of the various treatment approaches of head and neck cancer.

show abstract

“…After intravenous application cisplatin diffuses nonselectively, according to the concentration gradient, into all body cells. In the cell it hydrolyses to an aquaplatin (II) complex, which, according to common opinion, mostly forms DNA cross-links (22). In addition to this generally described pathway, cisplatin interacts with a number of other cell organelles as well as cellular membrane and their components.…”

Section: Damage By Cisplatin To Parotid Glandsmentioning

confidence: 99%

Effect of Cisplatin on Parotid Gland Function in Concomitant Radiochemotherapy

Hey

Setz

Gerlach

et al. 2009

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

Cisplatin and Radiotherapy in the Treatment of Locally Advanced Head and Neck Cancer

Cited by 65 publications

References 46 publications

Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity

Heritability and Linkage Analysis of Sensitivity to Cisplatin-Induced Cytotoxicity

A review of risk factors and genetic alterations in head and neck carcinogenesis and implications for current and future approaches to treatment

Effect of Cisplatin on Parotid Gland Function in Concomitant Radiochemotherapy

Contact Info

Product

Resources

About